Esperion rises, NanoString sinks after IPO
This article was originally published in Scrip
Investors paid as much as $17.40 per share to own a piece of the hypercholesterolemia drug developer Esperion Therapeutics during the company's first day of trading on 26 June, but the stock closed at $14.50 – up 3.6% from the $14 initial public offering price.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.